Two perspective trials on metformin combinatorial therapy with platinum-based chemotherapy in advanced NSCLC (Non-Small Cell Lung Cancer) showed a composed median overall survival of 17.5 months for patients with KRAS mutations with good tolerability, validating metformin clinical efficacy as adjuvant therapy in this setting [65]. Here, KRAS is linked to non-small cell lung carcinoma.